Last $0.84 USD
Change Today 0.00 / 0.00%
Volume 690.0
DDXS On Other Exchanges
Symbol
Exchange
OTC US
As of 11:26 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

diadexus inc (DDXS) Snapshot

Open
$0.84
Previous Close
$0.84
Day High
$0.84
Day Low
$0.84
52 Week High
10/21/13 - $2.23
52 Week Low
04/23/13 - $0.59
Market Cap
46.0M
Average Volume 10 Days
158.4K
EPS TTM
$-0.04
Shares Outstanding
54.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIADEXUS INC (DDXS)

Related News

No related news articles were found.

diadexus inc (DDXS) Related Businessweek News

No Related Businessweek News Found

diadexus inc (DDXS) Details

diaDexus, Inc., a life sciences company, focuses on the development and commercialization of cardiovascular diagnostic products addressing needs in cardiovascular disease. The company’s products include PLAC ELISA Test and the PLAC Activity Test that are designed to provide information over and above traditional risk factors, such as cholesterol levels to help identify individuals at risk of suffering a heart attack or stroke. Its PLAC ELISA Test is an aid in predicting risk for coronary heart disease and ischemic strokes associated with atherosclerosis; and PLAC Test for Lp-PLA2 Activity is an indicator of atherosclerotic cardiovascular disease. The company markets its diagnostic products to various national and regional clinical reference laboratories in the United States, Europe, and internationally. diaDexus, Inc. is based in South San Francisco, California.

67 Employees
Last Reported Date: 03/11/14

diadexus inc (DDXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $583.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $368.3K
Chief Business Officer
Total Annual Compensation: $410.9K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $379.3K
Compensation as of Fiscal Year 2013.

diadexus inc (DDXS) Key Developments

DiaDexus, Inc. Proposes Amendments to the Restated Certificate of Incorporation

diaDexus, Inc. announced that at the annual general meeting to be held on May 29, 2014, the board proposes the series of alternate amendments to the company's restated certificate of incorporation to effect, at the discretion of the board of directors, a reverse stock split of the company's common stock, whereby each outstanding 3, 4, 5, 6, 7 or 8 shares would be converted and changed into one share of common stock, and for any such reverse stock split determined by the board of directors, a reduction in the number of authorized shares of the company's common stock from 100,000,000 to 50,000,000.

diaDexus, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Revenue Guidance for the First Half, Second Half and Full Year of 2014

diaDexus, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total revenue of $6,722,000 compared with $5,419,000 for the same period last year. Income from operations was $15,000 compared with loss of $300,000 for the same period last year. Loss before income tax was $194,000 compared with $397,000 for the same period last year. Net loss was $194,000 or $0.00 basic and diluted per share compared with $397,000 or $0.01 basic and diluted per share for the same period last year. For the full year, the company reported total revenue of $24,884,000 compared with $20,776,000 for the same period last year. Loss from operations was $2,015,000 compared with $2,398,000 for the same period last year. Loss before income tax was $2,159,000 compared with $2,787,000 for the same period last year. Net loss was $2,164,000 or $0.04 basic and diluted per share compared with $2,789,000 or $0.05 basic and diluted per share for the same period last year. The company currently projects total revenues in the range of $26 to $28 million for the full year 2014, compared with $24.9 million for 2013. The company expects revenue growth for the full year 2014 over the prior year, however, revenue for the first half of the year is expected to be similar to the same period in 2013 due to lower than anticipated sales to a significant customer. The company is expanding its sales and marketing programs and expects positive revenue growth in the second half of 2014 as a result of these efforts.

diaDexus, Inc. Announces Exclusive U.S. Licensing Deal with Thermo Fisher Scientific, Inc. to Advance Risk Prediction in Heart Failure

diaDexus, Inc. announced an exclusive licensing and supply agreement with Thermo Fisher Scientific Inc. that will provide diaDexus with the ability to develop and commercialize three independent biomarkers (MR-proADM (midregional pro adrenomedullin), MR-proANP (midregional pro atrial natriuretic peptide), and CT-proET1 (C-terminal pro endothelin-1)) to aid in risk prediction and prognosis for heart failure. Under the terms of the agreement, diaDexus will have exclusive rights to develop and commercialize diagnostic clinical laboratory tests based on these biomarkers in the United States. diaDexus plans to conduct the necessary clinical studies needed to allow for regulatory submission and potential U.S. Food and Drug Administration (FDA) clearance for these tests in the future.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DDXS:US $0.84 USD 0.00

DDXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DDXS.
View Industry Companies
 

Industry Analysis

DDXS

Industry Average

Valuation DDXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIADEXUS INC, please visit www.diadexus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.